Literature DB >> 19402713

Using substrate specificity of antiplasmin-cleaving enzyme for fibroblast activation protein inhibitor design.

Kyung N Lee1, Kenneth W Jackson, Simon Terzyan, Victoria J Christiansen, Patrick A McKee.   

Abstract

Circulating antiplasmin-cleaving enzyme (APCE), a prolyl-specific serine proteinase, is essentially identical to membrane-inserted fibroblast activation protein (FAP) that is transiently expressed during epithelial-derived cancer growth. Human precursive alpha(2)-antiplasmin (Met-alpha(2)AP), the only known physiologic substrate for APCE, is cleaved N-terminally to Asn-alpha(2)AP that is rapidly cross-linked to fibrin and protects it from digestion by plasmin. Identifying a specific inhibitor of APCE/FAP continues to be intensely pursued. Recombinant FAP cleavage of peptide libraries of short amino acid sequences surrounding the scissile bond, -Pro(12)-Asn(13)-, indicated that P2 Gly and P1 Pro are required, just as we found for APCE. We examined cleavage of P4-P4' peptides, using 19 amino acid substitutions at each position and selected ones in P8-P5. K(m) values determined for peptide substrates showed that P7 Arg has the highest affinity for APCE. Peptide cleavage rate increased with Arg in P6 rather than P5 or native P7. Placing Arg in P4 or P8 reduced cleavage rates dramatically. Cleavage of substrates with extended peptide sequences before or after the scissile bond showed endopeptidase to be superior to dipeptidase activity for APCE. A substrate analogue inhibitor, Phe-Arg-(8-amino-3,6-dioxaoctanoic acid)-Gly-[r]-fluoropyrrolidide, inhibited APCE with a K(i) of 54 microM but not dipeptidyl peptidase IV even at 2 mM. The inhibitor also blocked cleavage of Met-alpha(2)AP with an IC(50) of 91 microM. Replacing Arg with Gly at the same distance from fluoropyrrolidide as P7 Arg is from P1 Pro reduced its inhibition of APCE approximately 10-fold. Results indicate that Arg at P5, P6, or P7 distances from P1 enhances affinity and efficiency of substrates or inhibitors toward APCE or FAP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19402713      PMCID: PMC4470291          DOI: 10.1021/bi900257m

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  34 in total

Review 1.  Talabostat.

Authors:  Charles Casey Cunningham
Journal:  Expert Opin Investig Drugs       Date:  2007-09       Impact factor: 6.206

2.  Synthesis and structure-activity relationship of N-acyl-Gly-, N-acyl-Sar- and N-blocked-boroPro inhibitors of FAP, DPP4, and POP.

Authors:  Thuy Tran; Clifford Quan; Conrad Yap Edosada; Mark Mayeda; Christian Wiesmann; Dan Sutherlin; Beni B Wolf
Journal:  Bioorg Med Chem Lett       Date:  2006-12-01       Impact factor: 2.823

3.  Electrostatic steering and ionic tethering in enzyme-ligand binding: insights from simulations.

Authors:  R C Wade; R R Gabdoulline; S K Lüdemann; V Lounnas
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

4.  Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha.

Authors:  Kathleen Aertgeerts; Irena Levin; Lihong Shi; Gyorgy P Snell; Andy Jennings; G Sridhar Prasad; Yanming Zhang; Michelle L Kraus; Shant Salakian; Vandana Sridhar; Robert Wijnands; Mike G Tennant
Journal:  J Biol Chem       Date:  2005-04-04       Impact factor: 5.157

5.  Ala657 and conserved active site residues promote fibroblast activation protein endopeptidase activity via distinct mechanisms of transition state stabilization.

Authors:  Sarah A Meadows; Conrad Yap Edosada; Mark Mayeda; Thuy Tran; Clifford Quan; Helga Raab; Christian Wiesmann; Beni B Wolf
Journal:  Biochemistry       Date:  2007-03-24       Impact factor: 3.162

6.  Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein.

Authors:  Kyung N Lee; Kenneth W Jackson; Victoria J Christiansen; Chung S Lee; Jin-Geun Chun; Patrick A McKee
Journal:  Blood       Date:  2005-10-13       Impact factor: 22.113

7.  The effect of a single nucleotide polymorphism on human alpha 2-antiplasmin activity.

Authors:  Victoria J Christiansen; Kenneth W Jackson; Kyung N Lee; Patrick A McKee
Journal:  Blood       Date:  2007-02-22       Impact factor: 22.113

8.  Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites.

Authors:  Saurabh Aggarwal; W Nathaniel Brennen; Thomas P Kole; Elizabeth Schneider; Ozlem Topaloglu; Melinda Yates; Robert J Cotter; Samuel R Denmeade
Journal:  Biochemistry       Date:  2007-12-21       Impact factor: 3.162

Review 9.  On the edge of validation--cancer protease fibroblast activation protein.

Authors:  Beni B Wolf; Clifford Quan; Thuy Tran; Christian Wiesmann; Daniel Sutherlin
Journal:  Mini Rev Med Chem       Date:  2008-06       Impact factor: 3.862

10.  Seprase, a membrane-type serine protease, has different expression patterns in intestinal- and diffuse-type gastric cancer.

Authors:  Kyoko Okada; Wen-Tien Chen; Satoshi Iwasa; Xin Jin; Tetsu Yamane; Akishi Ooi; Masako Mitsumata
Journal:  Oncology       Date:  2003       Impact factor: 2.935

View more
  9 in total

1.  Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor α2-antiplasmin.

Authors:  K N Lee; K W Jackson; V J Christiansen; E K Dolence; P A McKee
Journal:  J Thromb Haemost       Date:  2011-05       Impact factor: 5.824

2.  Comparative analysis of the substrate preferences of two post-proline cleaving endopeptidases, prolyl oligopeptidase and fibroblast activation protein α.

Authors:  Kalyani Jambunathan; Douglas S Watson; Aaron N Endsley; Krishna Kodukula; Amit K Galande
Journal:  FEBS Lett       Date:  2012-06-27       Impact factor: 4.124

Review 3.  Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy.

Authors:  W Nathaniel Brennen; John T Isaacs; Samuel R Denmeade
Journal:  Mol Cancer Ther       Date:  2012-02       Impact factor: 6.261

4.  Fibroblast activation protein α activatable theranostic pro-photosensitizer for accurate tumor imaging and highly-specific photodynamic therapy.

Authors:  Yong Luo; Zishan Zeng; Ting Shan; Xiaoyu Xu; Jie Chen; Yuanfeng He; Tao Zhang; Zeqian Huang; Guihong Chai; Yanjuan Huang; Yanfang Zhao; Chunshun Zhao
Journal:  Theranostics       Date:  2022-05-01       Impact factor: 11.600

5.  Fibroblast activation protein-α, a stromal cell surface protease, shapes key features of cancer associated fibroblasts through proteome and degradome alterations.

Authors:  M M Koczorowska; S Tholen; F Bucher; L Lutz; J N Kizhakkedathu; O De Wever; U F Wellner; M L Biniossek; A Stahl; S Lassmann; O Schilling
Journal:  Mol Oncol       Date:  2015-08-11       Impact factor: 6.603

6.  Targeting inhibition of fibroblast activation protein-α and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments.

Authors:  Victoria J Christiansen; Kenneth W Jackson; Kyung N Lee; Tamyra D Downs; Patrick A McKee
Journal:  Neoplasia       Date:  2013-04       Impact factor: 5.715

7.  Suppression of tumor growth in mice by rationally designed pseudopeptide inhibitors of fibroblast activation protein and prolyl oligopeptidase.

Authors:  Kenneth W Jackson; Victoria J Christiansen; Vivek R Yadav; Robert Silasi-Mansat; Florea Lupu; Vibhudutta Awasthi; Roy R Zhang; Patrick A McKee
Journal:  Neoplasia       Date:  2015-01       Impact factor: 5.715

8.  Alpha2-Antiplasmin: The Devil You Don't Know in Cerebrovascular and Cardiovascular Disease.

Authors:  Satish Singh; Sofiyan Saleem; Guy L Reed
Journal:  Front Cardiovasc Med       Date:  2020-12-23

9.  Circulating FGF21 proteolytic processing mediated by fibroblast activation protein.

Authors:  Eugene Y Zhen; Zhaoyan Jin; Bradley L Ackermann; Melissa K Thomas; Jesus A Gutierrez
Journal:  Biochem J       Date:  2015-12-03       Impact factor: 3.857

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.